Tag Archives: Bristol Myers Squibb

Judge Throws The Book At Former Bristol-Myers Squibb Exec

Media wordsmiths are competing to outdo one another today in punny reporting on the news that ex-BMS exec Andrew Bodnar has been sentenced to write a book about the role he played in the firm’s 2006 reverse-payments case over generic Plavix. “Pen-ance: Bristol-Myers Exec Gets Two Years of Hard Writing,” The Wall Street Journal Law […]
Posted in Legal | Also tagged , , , , , , , | Leave a comment

Gilead Making a Bundle

Gilead Sciences has once again proven that independent biotechs can innovate with the best of Big Pharma. The Silicon Valley company’s wizardry at weaving multiple drugs into a single weft enabled it to overthrow GlaxoSmithKline as king of HIV in 2007. Yesterday, at the 16th annual Congress of Retroviruses and Opportunistic Infections (CROI), the biotech […]
Posted in Biotech, Emerging Markets, R&D | Also tagged , , | Leave a comment

Lilly Puts Up $6.5 Billion for ImClone

Lilly broke the news Monday morning that ImClone had accepted its offer to acquire the biotech firm for $6.5 billion or $70 per share—Lilly’s largest acquisition ever. With this purchase Lilly gains control of ImClone’s blockbuster, targeted cancer agent Erbitux, which is marketed for second- and third-line colon cancer and refractory head and neck cancer. […]
Posted in Biotech, Deals | Also tagged , , , , , , , | 1 Comment
  • Categories

  • Meta